Abstract: Described is an oral thin film comprising at least one matrix layer, wherein the at least one matrix layer comprises at least one pharmaceutically active agent, at least one polyvinyl alcohol and at least one polyvinyl alcohol-polyethylene glycol graft copolymer, a method for producing same, and use thereof as a medicament.

Abstract: Hair treatment compositions, kits for producing such hair treatment compositions, and methods for using such kits and/or hair treatment compositions are provided for treating hair. Methods for treating hair typically include: obtaining a first composition comprising one or more polysaccharides with amine group(s) and water; adding ascorbic acid and one or more peroxides, peroxo compounds, or combinations thereof to the first composition to obtain a second composition; applying the second composition to hair; and heating the hair, which has the second composition applied thereto, to a temperature above 25° C. Kits for improving hair typically include a first composition comprising one or more polysaccharides with amine group(s) and water; a second composition comprising up to 100 wt. % of ascorbic acid; and a third composition comprising a peroxide, a peroxo compound, or a combination thereof, wherein the first composition, the second composition, and the third composition are separately contained.

Abstract: An orally disintegrating dosage form of a proton pump inhibitor, methods for its production and use thereof are provided. The dosage form includes a plurality of pellets containing a proton pump inhibitor admixed with a disintegrant to afford rapid disintegration in the oral cavity after administration.

Abstract: A method of making Cu—Ag3PO4 nanoparticles is provided. The method includes forming a mixture of at least one silver salt, at least one phosphate salt, and at least one copper (II) salt. The method further includes dissolving the mixture in water. The method further includes sonicating the mixture. The method further includes precipitating the Cu—Ag3PO4 nanoparticles or “nanoparticles”. The copper is present in the nanoparticles in an amount of 2 to 23 weight percent (wt. %) based on the total weight of the Cu—Ag3PO4. The nanoparticles of the present disclosure find application in treating cervical cancer, and colorectal cancer. The nanoparticles may also be used in photodegrading environmental pollutants.

Abstract: Described are macro-capsules and barriers that can be used to prepare therapeutic cell implants, methods of encapsulating therapeutic cells, and methods of using the encapsulated cells in the treatment of disease.

Abstract: One embodiment of a contact lens includes a lens body configured to fit directly on the surface of the eye and legible characters positioned on the lens body. Another embodiment of a contact lens comprises a lens body including polymeric material and a lens enhancing material (e.g., ink, silicone material, medicament material, and the like) encapsulated in the polymeric material. The lens enhancing material can be in the form of isolated sections distributed in the surrounding polymeric material. Methods of making contact lenses include forming a first lens layer including a first surface, forming a pattern on the first surface, and forming a second lens layer over the pattern.

Abstract: The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”). It also is directed to a method for making uncalcined HSS, calcined HSS from which phenyl groups have been removed, and HSS incorporating particles of Fe3O4, as well as compositions containing HSS.

Abstract: Tellurium nanowires synthesized using green chemistry methods and having unique morphologies and functional properties are provided. The nanowires have a core of hexagonal crystal phase tellurium and a polymer coating, and can be used for treating cancer without apparent cytotoxicity toward normal human cells.

Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.

Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.

Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.

Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.

Abstract: This invention relates to a naproxen formulation suitable for encapsulation into a soft gel dosage unit by increasing the stability, concentration, and bioavailability of naproxen. Fill formulations of the invention may include other active pharmaceutical ingredients and combinations of two or more active pharmaceutical ingredients. This invention also provides for adjusting pH values of fill formulations without additional process steps. A process for increasing the achievable concentration of an active NSAID pharmaceutical ingredient, such as naproxen, relative to fill composition for dosage units is also provided. The highly concentrated formulation of this invention permits a reduction in the fill volume or dosage unit size, or an increase in concentration of the active pharmaceutical ingredient per dosage form. The invention also relates to a formulation of optimal stability suitable for supporting a fill composition compatible with the soft gel dosage unit.

Abstract: A pH-responsive polymer formed of a biocompatible polymer to which a group which is electrically neutral under pH environments of more than 7 and which changes to be cationic at pH 7 or less is bonded.

Abstract: Provided are fast relaxing hydrogels that are useful for regulating cell behavior and enhancing tissue regeneration, e.g., bone regeneration.

Abstract: The present disclosure relates to hair-treatment compositions, typically in the form of an oil-in-water emulsion, comprising: (a) one or more monosaccharides with amine group(s); (b) one or more polysaccharides with amine group(s); wherein (a) and (b) are solubilized in an aqueous phase of the oil-in-water emulsion; (c) one or more oils; (d) one or more nonionic emulsifiers; and (e) water. The compositions strengthen hair fibers and provide additional cosmetic improvements to the hair such as conditioning, detangling, softness, suppleness, moisturizing, and manageability. Methods of treating hair with the compositions are also described. The methods include applying the composition to wet or damp hair, drying the hair (for example, with a blow dryer) and treating the hair with heat (for example, with a hot iron).

Abstract: An interpenetrating polymer network (IPN) structured hydrogel includes a crosslinked first natural polymer macromer with a first elasticity and an interpenetrating network of crosslinked second natural polymer macromers having a second elasticity higher than the first elasticity, the IPN structured hydrogel being cytocompatible, and, upon degradation, produce substantially non-toxic products.

Abstract: The present disclosure relates generally to tissue engineering. Disclosed herein are biomimetic sponges useful for tissue regeneration and methods for making biomimetic sponges.

Abstract: A fibrous substrate for the removal of Gram negative bacteria (Escherichia coli) from a surface is provided. The fibrous substrate includes a capturing agent, and the affinity of capturing for the Gram negative bacteria allows the fibrous substrate to capture the Gram negative bacteria, thereby removing the Gram negative bacteria from the surface and also inhibiting the spread of the Gram negative bacteria to other surfaces that may contact the fibrous substrate. Of particular advantage, the presence of the capturing agent on the fibrous substrate may help protect against the spread or infection of pathogens without the use of chemicals, such as antiseptics or antibiotics.

Abstract: A Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3 and a process for its preparation. The polymorphic mixture of Rifaximin is for use as a medicament, in particular in the treatment of traveler's diarrhea and hepatic encephalopathy. A pharmaceutical composition comprises the polymorphic mixture of Rifaximin as active ingredient, in particular, a solid formulation, more in particular, a film coated tablet. A polymorphic form of crude wet rifaximin and of purified wet rifaximin their use are used as intermediates in a process for the preparation of Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3.